Retatrutide, sammenfatning af evidensgrundlaget Vi ved: Fase 2 viser 24,2% vgttab ved 12 mg over 48 uger (NEJM 2023) Fase 3 TRIUMPH-1, det pivotale fedme-studie (2.339 deltagere), viser 28,3% over 80 uger, op til 30,3% ved 104-ugers forlngelse hos BMI35 (forr 2026) Fase 3 TRIUMPH-4 (knartrose-substudie) viser 28,7% over 68 uger (december 2025) Bivirkningsprofilen ligner semaglutide og tirzepatide Leverfedtreduktion p op til 82% i substudie Markant HbA1c-reduktion ved type 2-diabetes (Lancet 2023) Vi ved endnu ikke: Langsigtet sikkerhed ud over 68 uger Prcis effekt p muskelmasse Kardiovaskulrt outcome (TRIUMPH-3 afventer) Effekt ved ophr Endelig pris og tilskudsstatus i Danmark Retatrutide og mental sundhed, en overset dimension Fedme og mental sundhed er tt forbundne
However, it is critically important to state clearly: there is no peer-reviewed clinical evidence supporting the safety or efficacy of stacking retatrutide with any other peptide
This will likely delay how soon you can access the medication, but many doctors are familiar with the process and will help patients navigate it
Why women need a female-specific retatrutide dosing approach Pharmacokinetics differ by sex The assumption that one dose fits all has caused real harm in weight-loss pharmacology
